Activin receptor antagonists for cancer-related anemia and bone disease

First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.

(2017) J. Rodon Ahnert et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulated INHBA Expression May Promote Cell Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma

(2015) Christopher W. Seder et al.   NEOPLASIA

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

The influence of follistatin on mechanical properties of bone tissue in growing mice with overexpression of follistatin

(2012) Anna Gajos-Michniewicz et al.   JOURNAL OF BONE AND MINERAL METABOLISM

The specificities of small molecule inhibitors of the TGFß and BMP pathways

(2011) Janis Vogt et al.   CELLULAR SIGNALLING

Stress erythropoiesis: new signals and new stress progenitor cells

(2011) Robert F Paulson et al.   CURRENT OPINION IN HEMATOLOGY

Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide

(2011) Yogeshwar Makanji et al.   ENDOCRINOLOGY

Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands

(2011) Craig A. Harrison et al.   GROWTH FACTORS

Betaglycan: A multifunctional accessory

(2011) Maree Bilandzic et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

New insights into the mechanisms of activin action and inhibition

(2011) Kelly L. Walton et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Hematopoietic Growth Factors in Myelodysplastic Syndromes

(2011) David P. Steensma   SEMINARS IN ONCOLOGY

Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response

(2011) Maria Antsiferova et al.   Nature Communications

Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies

(2010) Shontelle Dodson et al.   Annual Review of Medicine

Follistatin as a potent regulator of bone metabolism

(2010) A. Gajos-Michniewicz et al.   BIOMARKERS

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

(2010) J. D. Rizzo et al.   BLOOD

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

Reduced SMAD7 Leads to Overactivation of TGF-  Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-  Receptor I Kinase

(2010) L. Zhou et al.   CANCER RESEARCH

Bone morphogenetic protein and bone metastasis, implication and therapeutic potential

(2010) Lin Ye   Frontiers in Bioscience-Landmark

Prodomains of Transforming Growth Factor β (TGFβ) Superfamily Members Specify Different Functions

(2010) Gerhard Sengle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Activin A and bone metastasis

(2010) Gaetano Leto   JOURNAL OF CELLULAR PHYSIOLOGY

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Follicle-stimulating hormone increases bone mass in female mice

(2010) C. M. Allan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Complex and Context Dependent Regulation of Hematopoiesis by TGF-β Superfamily Signaling

(2009) Sofie Singbrant Söderberg et al.   Annals of the New York Academy of Sciences

BMP4 regulates the hematopoietic stem cell niche

(2009) D. C. Goldman et al.   BLOOD

Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis)

(2009) Roberto José Fajardo et al.   BONE

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding

(2009) Jennifer N Cash et al.   EMBO JOURNAL

Strategies for TGF-β modulation: a review of recent patents

(2009) Dominique Bonafoux et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells

(2009) Paul D. Upton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

(2009) Kristy M. Nicks et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Anemia Management in Oncology and Hematology

(2009) J. L. Spivak et al.   ONCOLOGIST

Activin C Antagonizes Activin A in Vitro and Overexpression Leads to Pathologies in Vivo

(2008) Elspeth Gold et al.   AMERICAN JOURNAL OF PATHOLOGY

Inhibition of the TGF-  receptor I kinase promotes hematopoiesis in MDS

(2008) L. Zhou et al.   BLOOD

Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell-Depleted SCID Mice

(2008) H. Ogino et al.   CLINICAL CANCER RESEARCH

The silent risks of blood transfusion

(2008) James Rawn   Current Opinion in Anesthesiology

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators

(2008) Tatyana A. Souza et al.   MOLECULAR ENDOCRINOLOGY

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

(2007) Lorea Bueno et al.   EUROPEAN JOURNAL OF CANCER